M. Chileshe, Geoffrey Mupeta, M. Kasanga, Ruth Lindizyani Mfune, S. Mudenda, Mildred Biemba, Nzooma M Shimaponda-Mataa, M. Sinkala, V. Daka
{"title":"赞比亚成年人口接种covid -19疫苗后不良事件发生率","authors":"M. Chileshe, Geoffrey Mupeta, M. Kasanga, Ruth Lindizyani Mfune, S. Mudenda, Mildred Biemba, Nzooma M Shimaponda-Mataa, M. Sinkala, V. Daka","doi":"10.37871/jbres1389","DOIUrl":null,"url":null,"abstract":"Introduction: COVID-19 continues to be a public health concern despite several practical interventions to curb its spread. Now, widespread vaccination appears to be the most important strategy in winning the fight against this deadly pandemic by promoting herd immunity. However, a lack of independent and local studies on vaccines’ safety may adversely impact the vaccine uptake and eventually the overarching goal of reducing disease transmission. Objective: To determine the prevalence of adverse events post COVID-19 vaccination amongst the adult Zambia population. Methods: This was a descriptive cross-sectional study conducted among recipients of COVID-19 vaccines in Zambia. The study was conducted between July and August 2021. 584 adult individuals who had access to the questionnaire were enrolled. Relationships between patients' demographics and Adverse Events (AEs) were assessed using the chi-square (χ2) test given the categorical nature of the data. Results: Pain at the injection site (79.8%), headache (57.4%), fatigue (55.5%), chills (52.6%), fever (42.3%), and joint pains (37.5%) were the most commonly reported adverse events. When stratified by gender, pain at the injection site (p = 0.01), limitation of arm movement (p < 0.001), chills (p = 0.017), headache (p = 0.044), fatigue (p = 0.004), nausea or vomiting (p < 0.001) were statistically significant, with females mostly affected. There was a statistically significant difference in the case of limitation of arm movement (20.7% vs. 9.9%, p = 0.031), chills (54.8% vs. 36.6%, p = 0.004), headache (59.6% vs. 40.8%, p = 0.003) and fatigue (57.5% vs. 40.8%, p = 0.008) between those 49 years and below compared to those above 50 years. Conclusion: Our study provides evidence of adverse events being experienced by the recipient of COVID-19 vaccines and that these have been mainly mild. Healthcare authorities need to educate the public about the possible adverse events associated with COVID-19 vaccines and how to report these events should they experience some. This will improve pharmacovigilance of adverse events associated with COVID-19 vaccines.","PeriodicalId":94067,"journal":{"name":"Journal of biomedical research & environmental sciences","volume":"10 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Prevalence of Adverse Events Post-COVID-19 Vaccination amongst the Adult Zambian Population\",\"authors\":\"M. Chileshe, Geoffrey Mupeta, M. Kasanga, Ruth Lindizyani Mfune, S. Mudenda, Mildred Biemba, Nzooma M Shimaponda-Mataa, M. Sinkala, V. Daka\",\"doi\":\"10.37871/jbres1389\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: COVID-19 continues to be a public health concern despite several practical interventions to curb its spread. Now, widespread vaccination appears to be the most important strategy in winning the fight against this deadly pandemic by promoting herd immunity. However, a lack of independent and local studies on vaccines’ safety may adversely impact the vaccine uptake and eventually the overarching goal of reducing disease transmission. Objective: To determine the prevalence of adverse events post COVID-19 vaccination amongst the adult Zambia population. Methods: This was a descriptive cross-sectional study conducted among recipients of COVID-19 vaccines in Zambia. The study was conducted between July and August 2021. 584 adult individuals who had access to the questionnaire were enrolled. Relationships between patients' demographics and Adverse Events (AEs) were assessed using the chi-square (χ2) test given the categorical nature of the data. Results: Pain at the injection site (79.8%), headache (57.4%), fatigue (55.5%), chills (52.6%), fever (42.3%), and joint pains (37.5%) were the most commonly reported adverse events. When stratified by gender, pain at the injection site (p = 0.01), limitation of arm movement (p < 0.001), chills (p = 0.017), headache (p = 0.044), fatigue (p = 0.004), nausea or vomiting (p < 0.001) were statistically significant, with females mostly affected. There was a statistically significant difference in the case of limitation of arm movement (20.7% vs. 9.9%, p = 0.031), chills (54.8% vs. 36.6%, p = 0.004), headache (59.6% vs. 40.8%, p = 0.003) and fatigue (57.5% vs. 40.8%, p = 0.008) between those 49 years and below compared to those above 50 years. Conclusion: Our study provides evidence of adverse events being experienced by the recipient of COVID-19 vaccines and that these have been mainly mild. Healthcare authorities need to educate the public about the possible adverse events associated with COVID-19 vaccines and how to report these events should they experience some. This will improve pharmacovigilance of adverse events associated with COVID-19 vaccines.\",\"PeriodicalId\":94067,\"journal\":{\"name\":\"Journal of biomedical research & environmental sciences\",\"volume\":\"10 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of biomedical research & environmental sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.37871/jbres1389\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of biomedical research & environmental sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37871/jbres1389","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
摘要
导言:尽管采取了一些实际干预措施来遏制其传播,但COVID-19仍然是一个公共卫生问题。现在,广泛接种疫苗似乎是通过促进群体免疫来赢得对抗这种致命大流行的最重要战略。然而,缺乏对疫苗安全性的独立和本地研究可能会对疫苗的吸收产生不利影响,并最终影响减少疾病传播的总体目标。目的:了解赞比亚成人COVID-19疫苗接种后不良事件的发生率。方法:这是一项在赞比亚COVID-19疫苗接种者中进行的描述性横断面研究。该研究于2021年7月至8月进行。参与调查的584名成年人参与了调查。考虑到数据的分类性质,采用χ2检验评估患者人口统计学特征与不良事件(ae)之间的关系。结果:注射部位疼痛(79.8%)、头痛(57.4%)、疲劳(55.5%)、寒战(52.6%)、发热(42.3%)和关节痛(37.5%)是最常见的不良反应。按性别分层时,注射部位疼痛(p = 0.01)、手臂活动受限(p < 0.001)、寒战(p = 0.017)、头痛(p = 0.044)、疲劳(p = 0.004)、恶心或呕吐(p < 0.001)均有统计学意义,且以女性为主。49岁及以下患者与50岁以上患者在手臂活动受限(20.7% vs. 9.9%, p = 0.031)、寒战(54.8% vs. 36.6%, p = 0.004)、头痛(59.6% vs. 40.8%, p = 0.003)和疲劳(57.5% vs. 40.8%, p = 0.008)方面的差异有统计学意义。结论:我们的研究提供了COVID-19疫苗接种者经历不良事件的证据,这些不良事件主要是轻微的。卫生保健当局需要教育公众了解与COVID-19疫苗相关的可能不良事件,以及如果他们遇到这些事件,如何报告这些事件。这将提高与COVID-19疫苗相关不良事件的药物警惕性。
Prevalence of Adverse Events Post-COVID-19 Vaccination amongst the Adult Zambian Population
Introduction: COVID-19 continues to be a public health concern despite several practical interventions to curb its spread. Now, widespread vaccination appears to be the most important strategy in winning the fight against this deadly pandemic by promoting herd immunity. However, a lack of independent and local studies on vaccines’ safety may adversely impact the vaccine uptake and eventually the overarching goal of reducing disease transmission. Objective: To determine the prevalence of adverse events post COVID-19 vaccination amongst the adult Zambia population. Methods: This was a descriptive cross-sectional study conducted among recipients of COVID-19 vaccines in Zambia. The study was conducted between July and August 2021. 584 adult individuals who had access to the questionnaire were enrolled. Relationships between patients' demographics and Adverse Events (AEs) were assessed using the chi-square (χ2) test given the categorical nature of the data. Results: Pain at the injection site (79.8%), headache (57.4%), fatigue (55.5%), chills (52.6%), fever (42.3%), and joint pains (37.5%) were the most commonly reported adverse events. When stratified by gender, pain at the injection site (p = 0.01), limitation of arm movement (p < 0.001), chills (p = 0.017), headache (p = 0.044), fatigue (p = 0.004), nausea or vomiting (p < 0.001) were statistically significant, with females mostly affected. There was a statistically significant difference in the case of limitation of arm movement (20.7% vs. 9.9%, p = 0.031), chills (54.8% vs. 36.6%, p = 0.004), headache (59.6% vs. 40.8%, p = 0.003) and fatigue (57.5% vs. 40.8%, p = 0.008) between those 49 years and below compared to those above 50 years. Conclusion: Our study provides evidence of adverse events being experienced by the recipient of COVID-19 vaccines and that these have been mainly mild. Healthcare authorities need to educate the public about the possible adverse events associated with COVID-19 vaccines and how to report these events should they experience some. This will improve pharmacovigilance of adverse events associated with COVID-19 vaccines.